Vaccine protection against SIVmac239 acquisition

Mauricio Martins, Georg F. Bischof, Young C. Shin, William A. Lauer, Lucas Gonzalez-Nieto, David Watkins, Eva G. Rakasz, Jeffrey D. Lifson, Ronald Charles Desrosiers

Research output: Contribution to journalArticle

Abstract

The biological characteristics of HIV pose serious difficulties for the success of a preventive vaccine. Molecularly cloned SIVmac239 is difficult for antibodies to neutralize, and a variety of vaccine approaches have had great difficulty achieving protective immunity against it in rhesus monkey models. Here we report significant protection against i.v. acquisition of SIVmac239 using a long-lasting approach to vaccination. The vaccine regimen includes a replication-competent herpesvirus engineered to contain a near-full-length SIV genome that expresses all nine SIV gene products, assembles noninfectious SIV virion particles, and is capable of eliciting long-lasting effector-memory cellular immune responses to all nine SIV gene products. Vaccinated monkeys were significantly protected against acquisition of SIVmac239 following repeated marginal dose i.v. challenges over a 4-month period. Further work is needed to define the critical components necessary for eliciting this protective immunity, evaluate the breadth of the protection against a variety of strains, and explore how this approach may be extended to human use.

Original languageEnglish (US)
Pages (from-to)1739-1744
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume116
Issue number5
DOIs
StatePublished - Jan 29 2019

Fingerprint

Vaccines
Immunity
Herpesviridae
Macaca mulatta
Cellular Immunity
Virion
Genes
Haplorhini
Vaccination
HIV
Genome
Antibodies

Keywords

  • AIDS vaccine
  • DNA electroporation
  • HIV
  • Recombinant herpesvirus
  • SIV

ASJC Scopus subject areas

  • General

Cite this

Vaccine protection against SIVmac239 acquisition. / Martins, Mauricio; Bischof, Georg F.; Shin, Young C.; Lauer, William A.; Gonzalez-Nieto, Lucas; Watkins, David; Rakasz, Eva G.; Lifson, Jeffrey D.; Desrosiers, Ronald Charles.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 116, No. 5, 29.01.2019, p. 1739-1744.

Research output: Contribution to journalArticle

Martins, Mauricio ; Bischof, Georg F. ; Shin, Young C. ; Lauer, William A. ; Gonzalez-Nieto, Lucas ; Watkins, David ; Rakasz, Eva G. ; Lifson, Jeffrey D. ; Desrosiers, Ronald Charles. / Vaccine protection against SIVmac239 acquisition. In: Proceedings of the National Academy of Sciences of the United States of America. 2019 ; Vol. 116, No. 5. pp. 1739-1744.
@article{2dd9e611e8ff4c4ca5e316f756bb5fb2,
title = "Vaccine protection against SIVmac239 acquisition",
abstract = "The biological characteristics of HIV pose serious difficulties for the success of a preventive vaccine. Molecularly cloned SIVmac239 is difficult for antibodies to neutralize, and a variety of vaccine approaches have had great difficulty achieving protective immunity against it in rhesus monkey models. Here we report significant protection against i.v. acquisition of SIVmac239 using a long-lasting approach to vaccination. The vaccine regimen includes a replication-competent herpesvirus engineered to contain a near-full-length SIV genome that expresses all nine SIV gene products, assembles noninfectious SIV virion particles, and is capable of eliciting long-lasting effector-memory cellular immune responses to all nine SIV gene products. Vaccinated monkeys were significantly protected against acquisition of SIVmac239 following repeated marginal dose i.v. challenges over a 4-month period. Further work is needed to define the critical components necessary for eliciting this protective immunity, evaluate the breadth of the protection against a variety of strains, and explore how this approach may be extended to human use.",
keywords = "AIDS vaccine, DNA electroporation, HIV, Recombinant herpesvirus, SIV",
author = "Mauricio Martins and Bischof, {Georg F.} and Shin, {Young C.} and Lauer, {William A.} and Lucas Gonzalez-Nieto and David Watkins and Rakasz, {Eva G.} and Lifson, {Jeffrey D.} and Desrosiers, {Ronald Charles}",
year = "2019",
month = "1",
day = "29",
doi = "10.1073/pnas.1814584116",
language = "English (US)",
volume = "116",
pages = "1739--1744",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "5",

}

TY - JOUR

T1 - Vaccine protection against SIVmac239 acquisition

AU - Martins, Mauricio

AU - Bischof, Georg F.

AU - Shin, Young C.

AU - Lauer, William A.

AU - Gonzalez-Nieto, Lucas

AU - Watkins, David

AU - Rakasz, Eva G.

AU - Lifson, Jeffrey D.

AU - Desrosiers, Ronald Charles

PY - 2019/1/29

Y1 - 2019/1/29

N2 - The biological characteristics of HIV pose serious difficulties for the success of a preventive vaccine. Molecularly cloned SIVmac239 is difficult for antibodies to neutralize, and a variety of vaccine approaches have had great difficulty achieving protective immunity against it in rhesus monkey models. Here we report significant protection against i.v. acquisition of SIVmac239 using a long-lasting approach to vaccination. The vaccine regimen includes a replication-competent herpesvirus engineered to contain a near-full-length SIV genome that expresses all nine SIV gene products, assembles noninfectious SIV virion particles, and is capable of eliciting long-lasting effector-memory cellular immune responses to all nine SIV gene products. Vaccinated monkeys were significantly protected against acquisition of SIVmac239 following repeated marginal dose i.v. challenges over a 4-month period. Further work is needed to define the critical components necessary for eliciting this protective immunity, evaluate the breadth of the protection against a variety of strains, and explore how this approach may be extended to human use.

AB - The biological characteristics of HIV pose serious difficulties for the success of a preventive vaccine. Molecularly cloned SIVmac239 is difficult for antibodies to neutralize, and a variety of vaccine approaches have had great difficulty achieving protective immunity against it in rhesus monkey models. Here we report significant protection against i.v. acquisition of SIVmac239 using a long-lasting approach to vaccination. The vaccine regimen includes a replication-competent herpesvirus engineered to contain a near-full-length SIV genome that expresses all nine SIV gene products, assembles noninfectious SIV virion particles, and is capable of eliciting long-lasting effector-memory cellular immune responses to all nine SIV gene products. Vaccinated monkeys were significantly protected against acquisition of SIVmac239 following repeated marginal dose i.v. challenges over a 4-month period. Further work is needed to define the critical components necessary for eliciting this protective immunity, evaluate the breadth of the protection against a variety of strains, and explore how this approach may be extended to human use.

KW - AIDS vaccine

KW - DNA electroporation

KW - HIV

KW - Recombinant herpesvirus

KW - SIV

UR - http://www.scopus.com/inward/record.url?scp=85060784477&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060784477&partnerID=8YFLogxK

U2 - 10.1073/pnas.1814584116

DO - 10.1073/pnas.1814584116

M3 - Article

VL - 116

SP - 1739

EP - 1744

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 5

ER -